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We reviewed medical records of patients without known 
HIV and with positive cultures for nontuberculous mycobac-
teria (NTM) isolated during 2000–2003 from 1 large hospital 
in New York, New York. Overall, 505 patients had positive 
NTM cultures; 119 (24%) met the criteria for NTM disease. 
The difference between demographic characteristics of 
case-patients in our study (66% female, 61% white, and 
59% >60 years of age) and those of the base population 
as determined by regional census data was statistically sig-
niﬁ  cant. Estimated incidences for positive cultures, all dis-
ease, and respiratory tract disease were 17.7, 2.7, and 2.0 
per 100,000 persons, respectively. More patients with rap-
idly growing mycobacteria (61%), Mycobacterium kansasii 
(70%), or M. marinum (100%) met criteria for disease than 
did patients with M. avium complex (MAC) (27%, (p<0.01). 
NTM disease in patients without HIV is increasing. Labo-
ratory-based surveillance may be useful for detecting non-
MAC and non–respiratory tract disease.  
A
lthough the pathogenic potential of nontuberculous 
mycobacteria (NTM) was reported throughout the 
20th century, widespread appreciation of the clinical syn-
dromes caused by NTM began during the 1980s in associa-
tion with the AIDS pandemic and the consequent dramatic 
increase in disseminated Mycobacterium avium complex 
(MAC) infections (1,2). However, the epidemiology of 
NTM disease in patients without HIV infection remains 
somewhat difﬁ  cult to determine. NTM disease is relatively 
uncommon (3); it is not a reportable health event, and en-
vironmental exposure varies greatly by geographic region 
(1,4). Further, clinically insigniﬁ  cant colonization or con-
tamination can be difﬁ  cult to distinguish from true disease, 
which can render laboratory-based surveillance potentially 
inaccurate (5), and the risk factors for disease have not yet 
been fully deﬁ  ned.
To expand our understanding of the epidemiology of 
NTM, we reviewed the demographic and clinical charac-
teristics of patients without known HIV infection who had 
positive cultures for NTM from 2000–2003. We sought to 
determine the incidence of NTM disease and colonization, 
the risk factors for NTM disease, and the species of myco-
bacteria associated with different clinical syndromes at our 
urban medical center.
Methods
Study Design and Site
We conducted a retrospective study of patients without 
known HIV infection and with positive cultures for NTM 
obtained during 2000–2003 at Columbia University Medi-
cal Center (CUMC), New York-Presbyterian Hospital, the 
only medical center in northern Manhattan. The study was 
approved by the Institutional Review Board of Columbia 
University. 
Study Patients
Study patients had positive cultures for NTM and no 
laboratory evidence of HIV infection. Our mycobacteriol-
ogy laboratory compiled the medical record numbers of pa-
tients with positive NTM cultures from 2000 through 2003. 
To maintain privacy regarding HIV status, the list was elec-
tronically purged of the names of patients with positive HIV 
serologic test results, patients with HIV viral load, and pa-
tients who had had genotyping studies performed. Patients 
identiﬁ  ed in clinical notes as HIV infected were excluded.
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Data Collection
Demographic characteristics, coexisting medical ill-
nesses, and results of computed tomography (CT) studies 
of the chest and mycobacteriologic studies were collected 
from electronic medical records. These records were gener-
ally complete for demographic characteristics and clinical 
microbiology laboratory, surgical, and radiographic reports 
but sometimes lacked progress notes or treatment records, 
which were often written by hand in bedside charts. Elec-
tronic medical records were considered adequate to assess 
risk factors if the clinical notes (progress notes, consulta-
tion notes, discharge summaries) documented the medical 
history, coexisting illnesses, and medication regimens, in-
cluding use of antimycobacterial agents. 
Case Deﬁ  nitions of NTM 
Patients with blood cultures or tissue biopsy specimens 
positive for NTM were considered to have NTM disease. 
Patients with positive respiratory tract cultures were con-
sidered to have pulmonary disease if they met the follow-
ing American Thoracic Society (ATS) guidelines (6): chest 
CT scan performed within 6 months of an NTM-positive 
culture demonstrating inﬁ  ltrates, nodules, cavities, bron-
chiectasis, or tree-in-bud formations and >3 NTM-positive 
respiratory cultures; 2 positive cultures with >1 positive ac-
id-fast smear; or 1 positive culture with moderate, many, or 
heavy acid-fast bacilli noted on smear. Patients were con-
sidered not to have disease if NTM had been isolated from 
stool or urine or if a nonpathogenic NTM species (e.g., M. 
gordonae or M. gastri) had been isolated but symptoms at-
tributed to another etiology.
Estimated Incidence of NTM Disease
We estimated the annual incidence of NTM disease 
by using previously described methods (7). Since the to-
tal population at risk was unknown, we calculated a rough 
incidence estimate by studying only those patients with 
positive NTM cultures who resided in the geographic area, 
which was closer to CUMC than to any other New York 
City hospital. Residents in this area, which encompassed 
5 ZIP codes, were assumed to have the highest probability 
of receiving medical care at CUMC, and in fact, these ZIP 
codes were the most commonly noted among patients at 
CUMC. The number of cases of NTM disease diagnosed 
in this geographic subset per year was then divided by the 
2000 US Census population for the same area to calculate 
the incidence estimate (8). The population was adjusted 
downward by 1.5% based on current estimates of the HIV/
AIDS prevalence in New York City. 
Demographic and Geographic Analysis
The demographic characteristics of the study patients 
were compared with those of the New York Public Health 
Department (NYPH) catchment population using 2000 US 
Census data (8). We calculated the distribution of sex and 
race in the catchment population from weighted census 
tract data. To evaluate the potential role of environmental 
exposure, we compared the distribution of the residence 
ZIP codes of patients with NTM isolates to the ZIP codes 
of all CUMC patients.
Statistical Analysis
Associations and conﬁ  dence intervals (CIs) were cal-
culated with SAS 9.1 (SAS Institute Inc., Cary, NC, USA) 
and EpiInfo 3.3.2 (Centers for Disease Control and Pre-
vention, Atlanta, GA, USA). Single-proportion CIs were 
derived from the binomial distribution with continuity cor-
rection. We calculated CIs for the incidence estimate by us-
ing the formula provided by the National Center for Health 
Statistics (9). Median ages were compared by using the 
Mann-Whitney-Wilcoxon test. Univariate and multivariate 
associations between clinical and mycobacteriology data 
used Fisher exact test and logistic regression, respectively. 
Reported CIs and 2-tailed p values were for the 95% conﬁ  -
dence level; p values are given without correction for mul-
tiple comparisons. 
Results
During the 4-year study period, the clinical microbiol-
ogy laboratory identiﬁ  ed 769 patients with at least 1 posi-
tive NTM culture. Of these, 264 were excluded from fur-
ther analysis by electronic purge of HIV-infected patients 
as previously described (Figure 1). The remaining 505 
study patients had 820 positive NTM cultures; 282 (56%) 
were hospitalized when their ﬁ  rst positive NTM culture 
was obtained. MAC and the rapidly growing mycobacteria 
(RGM) species were most common, isolated from 84% (n 
= 422) and 9% (n = 45) of patients, respectively (Table 1).
Proportion of Patients with NTM Disease
Of the 505 study patients with NTM-positive cul-
tures, 375 (74%) had adequate clinical data to determine 
disease status. In all, 119 (32%) of 375 were considered 
to have NTM disease (Table 1, Figure 1). A signiﬁ  cantly 
higher proportion of patients with RGM (61%), M. kansasii 
(70%), or M. marinum (100%) isolates were categorized 
with disease compared with those with MAC (27%) iso-
lates (p<0.01).
Body Site and NTM Species
Respiratory Tract
Although only 24% (81/344) of patients with NTM-
positive cultures from the respiratory tract met ATS cri-
teria for NTM disease, 68% of cases of disease occurred 
in the respiratory tract (Table 2). However, MAC, RGM, 
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M. xenopi, and M. kansasii caused 80%, 9%, 6%, and 5% of 
these cases, respectively. No NTM species predicted disease; 
although a higher proportion of patients with M. kansasii 
(57%) and M. xenopi (44%) isolates were categorized with 
disease compared with MAC (25%); these differences were 
not statistically signiﬁ  cant (p = 0.08 and 0.24, respectively). 
No patient with M. gordonae, M. ﬂ  avescens, or M. scrofula-
ceum isolates met ATS criteria for disease.
Skin, Soft Tissue, and Surgical Wounds 
Skin and soft tissue sites were the second most com-
mon sites of disease and occurred in 21 (18%) patients. 
RGM caused 4 (33%) of 12 nonsurgical skin and soft tis-
sue infections and 7 (78%) of 9 surgical wound infections. 
Seven of the latter were associated with cosmetic proce-
dures; 4 had been performed in the Dominican Republic, 
2 in Ecuador, and 1 in the United States. All 4 cases of M. 
marinum infection occurred in the upper extremities. 
Bloodstream Infections and Disseminated Disease 
Seven patients had bloodstream infections (5 with RGM 
and 2 with MAC). Two additional subjects had positive blood 
cultures (both with MAC) and other infected body sites and, 
thus, were categorized with disseminated disease.
Gastrointestinal (GI) Tract Isolates 
Of the 11 patients with MAC cultured from the GI 
tract, 7 had adequate clinical information to assess disease 
status. Two (29%) of 7 had disseminated disease as de-
scribed above, and 5 had no clinical signs or symptoms of 
infection. 
Urine Isolates
No patients had NTM disease of the urinary tract. One 
patient had 4 urine cultures positive for MAC but was not 
categorized as having NTM disease because no symptoms 
of urinary tract infection and no treatment with antimyco-
bacterial agents had been documented.
Estimated Incidence of NTM Disease
Data from the 2000 US Census showed that 276,032 
people resided within 5 ZIP codes that are closer to our 
medical center than any other hospital. During the study 
period, 37% of the 536,875 patients cared for at CUMC 
listed their home addresses within these 5 ZIP codes. Ad-
justed for the HIV prevalence rate of ≈1.5% in New York 
City, the base HIV-negative population was 271,892. 
Overall, 192 (38%) of 505 patients with positive cultures 
for NTM and 29 (24%) of  119 patients with NTM disease 
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Figure 1. Flowchart of patient selection for cases of nontuberculous 
mycobacteria (NTM) colonization and NTM disease among patients 
without HIV infection, New York–Presbyterian Hospital (NYPH), 
Columbia University Medical Center, 2000–2003. 
Table 1. HIV-negative patients with positive nontuberculous mycobacteria cultures and disease, New York–Presbyterian Hospital, 
Columbia University Medical Center, New York, New York, 2000–2003 
NTM species*  No. positive cultures 
Adequate data to assess case 
status† No. patients with disease (%)‡ 
All species 505 375 119 (32) 
Mycobacterium avium complex (MAC)  422 297 79 (27) 
Rapidly growing mycobacteria‡   45 41 25 (61) 
M. abscessus 14 13 11 (85) 
M. chelonae 15 13 4 (31) 
M. fortuitum 16 15 10 (67) 
M. gordonae 25 6 0
M. kansasii‡1 2 1 0 7  ( 7 0 )  
M. marinum‡ 4 4 4 (100) 
M. scrofulaceum 54 0
M. xenopi 13 9 5 (56) 
*M. flavescens, M. gastri, M. haemophilum, and M. neoaurum were isolated once each.  
†Patients with adequate clinical, radiographic, and mycobacteriologic data to assess case status.  
‡Greater proportion of rapidly growing mycobacteria, M. kansasii, and M. marinum caused nontuberculous mycobacteria disease when compared with 
MAC (p<0.01). Mycobacteria in Patients without HIV
resided in this same area. Thus, the estimated annual inci-
dences of patients with positive NTM cultures in the area 
deﬁ  ned by these 5 ZIP codes, NTM disease (inclusive of 
the respiratory tract), and NTM disease speciﬁ  cally of the 
respiratory tract were 17.7 (95% CI 15.2–20.2), 2.7 (95% 
CI 1.8–3.8), and 2.0 (95% CI 1.3–3.1) cases per 100,000 
persons, respectively.
Demographic Characteristics
Sex
By adjusting 2000 US Census data for age, the expect-
ed proportion of women in the base population was 57% 
(Figure 2). The same proportion was observed in patients 
with NTM-positive cultures (57.0%, 95% CI = 52.6%–
61.4%). In contrast, patients with NTM disease were signif-
icantly more likely to be female than were those in the base 
population (66.4%, p = 0.04). Among those with disease 
of the respiratory tract caused by MAC, the distribution of 
patients by sex was similar to that of the base population 
(60.0% female, p = 0.71).
Race and Ethnicity 
The overall distribution of race and ethnicity was sig-
niﬁ  cantly different for patients with positive NTM cultures 
(p<0.01) or disease (p<0.001) when compared with the 
age-adjusted base population (Figure 3). A greater propor-
tion of patients with NTM disease were white and fewer 
were Hispanic. Similarly, patients with NTM disease were 
more likely to be white than patients with a positive culture 
(61% vs. 48%, p = 0.008).
Age 
The median age of the study patients with positive 
NTM cultures was 66 years. Most (59%, n = 70) patients 
with disease were >60 years of age; only 8% (n = 9) were 
children <15 years of age. Patients with MAC disease were 
older than those with RGM disease (68 vs. 53 years of age, 
respectively, p<0.01). The median ages of patients with 
disease of the respiratory tract caused by different species 
were similar (71 years vs. 69 years of age for MAC and 
RGM, respectively); patients with nonpulmonary disease 
caused by MAC were substantially younger than those with 
nonpulmonary disease caused by RGM (11 vs. 41 years of 
age, respectively). 
Geographic Distribution of Patients
The ZIP codes of patients with positive NTM cul-
tures were compared with those of all patients registered 
at CUMC. Patients with positive cultures were less likely 
to live in northern Manhattan within 3 miles of the medical 
center than were the hospital’s overall patient population 
(OR 0.72, p<0.001). In contrast, substantially more patients 
with positive cultures resided in the northwestern area of 
the Bronx (OR 2.17, p<0.001) or in Staten Island (OR 2.25, 
p<0.001). 
Coexisting Illness and Concomitant Medications
At least 1 coexisting illness or concomitant medication 
considered to be a potential risk factor for NTM disease 
was noted for 73% of patients who fulﬁ  lled the study case 
deﬁ  nitions for disease. Ninety-four (79%) of 119 patients 
with NTM disease had adequate data to assess their medical 
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Table 2. Site of disease and species of nontuberculous mycobacteria, New York–Presbyterian Hospital, Columbia University Medical
Center, New York, New York, 2000–2003*
Site of disease 
No. patients with 
MAC infection
No. patients with 
RGM infection
No. patients with other 
species infections  Total no. patients (%) 
Respiratory tract  65 7 9 81 (68.1) 
Skin and soft tissue, nonsurgical  2 4 6 12 (10.1) 
Surgical sites  0 7 2 9 (7.6) 
Bloodstream 2 4 1 7 (5.9) 
Lymph node  5 1 0 6 (5.0) 
Disseminated 2 0 0 2 (1.7)
Central nervous system  0 1 0 1 (0.8) 
Gastrointestinal tract  0 0 1 1 (0.8) 
All body sites  76 24 19 119 (100) 
*MAC, Mycobacterium avium complex; RGM, rapidly growing mycobacteria. 
Figure 2. Distribution by sex of patients with positive nontuberculous 
mycobacteria (NTM) cultures, NTM disease, and disease of the 
respiratory tract caused by Mycobacterium avium complex (MAC), 
New York–Presbyterian Hospital, Columbia University Medical 
Center, 2000–2003, compared with age-adjusted base population 
from 2000 US Census data. RESEARCH
histories, and 66% (62/94) had >1 coexisting illness (Table 
3). Preexisting lung disease was most common (44%), 
and patients with respiratory tract disease with NTM were 
more likely to have preexisting lung disease than patients 
with disease of other body sites (OR18, 95% CI 4.9–64, 
p<0.001). 
Eighteen percent of patients had >1 immunosup-
pressive condition (other than transplantation), including 
diabetes mellitus (14%), chronic renal failure (4%), or 
rheumatologic disease (5%), and 17% had solid organ or 
hematologic malignancy. When site of disease (respiratory 
tract vs. nonrespiratory tract) was adjusted for, patients 
with MAC disease were more likely to be transplant recipi-
ents than were patients with disease caused by other NTM 
species (OR 7.2, p = 0.01). 
For 79 (66%) of 119 patients with NTM disease, data 
were adequate to assess concomitant medications. Steroids 
or other immunosuppressive medications were prescribed 
for 25% and 15% of patients, respectively, within the 6 
months before the ﬁ  rst positive NTM culture. Although the 
use of steroids did not predict the site of NTM disease, the 
use of other immunosuppressive medications was less com-
mon in those with disease of the respiratory tract compared 
with those with disease of nonrespiratory sites (OR 0.30, 
95% CI 0.10–0.89, p<0.05). However, when body site was 
adjusted for, patients with MAC were more likely to have 
received steroids than were those infected with other spe-
cies (OR 5.2, 95% CI 1.2–24, p = 0.03). Also, more patients 
with bloodstream infections received cancer chemothera-
peutics than did patients with disease of other body sites 
(OR 28, 95% CI 3.6–220, p<0.01).
Discussion
This study is one of the largest recent studies of NTM 
and reﬂ  ects the current epidemiology and risk factors for 
disease and colonization with these microorganisms as as-
sessed in our medical center in northern Manhattan. The 
rate of NTM disease observed in patients without HIV in-
fection appears to be increasing, but it is difﬁ  cult to com-
pare studies because different epidemiologic methodols 
have been used. In a laboratory survey from 1993 to 1996 
performed by the Centers for Disease Control and Preven-
tion, the rate of positive NTM cultures was 7.5–8.2 cases 
per 100,000 persons, compared with our positive culture 
rate of 17.7 per 100,000 (5). The rate of NTM disease 
derived from several studies conducted through the mid-
1990s was estimated to be 2 per 100,000 (10). Surveys 
conducted in Europe estimated the rate of respiratory tract 
disease with MAC to be 0.2 cases per 100,000, and investi-
gators in the United Kingdom estimated the rate of disease 
of any body site to be 0.8–3.1 per 100,000 (11,12). We pre-
sented higher estimates of the incidence of NTM respira-
tory tract disease (2.0 per 100,000) and disease of any body 
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Figure 3. Distribution by race of patients with positive nontuberculous 
mycobacteria (NTM) cultures, NTM disease, and disease of the 
respiratory tract caused by Mycobacterium avium complex (MAC), 
New York–Presbyterian Hospital, Columbia University Medical 
Center, 2000–2003, compared with age-adjusted base population 
from 2000 US Census data.
Table 3. Comparison of coexisting conditions and concomitant medications with body site of nontuberculous mycobacteria (NTM) 
disease, New York–Presbyterian Hospital, Columbia University Medical Center, New York, New York, 2000–2003 
% Patients with coexisting condition (n = 94) 
Site of NTM disease  Lung disease Transplant recipient Immunocompromised*  Cancer None
Blood (n = 7)  0 0 33 67 0
Respiratory tract (n = 81)  63 9 16 13 28
Skin and soft tissue, surgical sites 
(n = 21) 
61 9 2 5 6 6 2
All† 44 11 18 17 34
% Patients receiving concomitant medications (n = 79) 
Site of NTM disease 
Systemic 
steroids Immunosuppressants Chemotherapeutics Immunomodulators None   
Blood (n = 7)  50 33 50 17 17
Respiratory tract (n = 81)  26 13 2 4 70
Skin and soft tissue, surgical sites 
(n = 21) 
17 17 8 8 75
All† 25 15 6 5 66
*Defined as diabetes, chronic renal failure and/or rheumatologic disease. 
†Includes 2 patients with disseminated disease following bone marrow transplantation, 1 patient with central nervous system disease receiving steroids, 1 
patient with gastrointestinal disease, and 2 patients with lymph node disease/cancer. Mycobacteria in Patients without HIV
site (2.7 per 100,000), potentially attributable, in part, to 
improved detection methods. However, our incidence cal-
culation may actually have underestimated the rate of NTM 
disease if persons who resided in the 5 ZIP codes of interest 
received care for NTM at another medical facility. Alterna-
tively, had we used a larger geographic region to calculate 
incidence, we may have compounded the underestimate 
because additional persons most likely would have sought 
care at medical facilities other than CUMC. Nevertheless, 
in the absence of mandatory statewide or nationwide re-
porting, large institution-based studies can produce the best 
incidence data.
Variation in the rates of NTM disease and colonization 
among different populations may also reﬂ  ect differences in 
the risk for exposure to environmental mycobacteria. Our 
data demonstrate geographic variations in the incidence 
of NTM disease within New York City. Although neigh-
borhood demographics may act as confounding variables, 
these ﬁ  ndings suggest that environmental factors deserve 
further study. For example, patients residing in the north-
western Bronx had higher rates of disease with NTM; this 
area receives water from the smaller Croton Reservoir as 
opposed to the Catskills-Delaware Reservoir that supplies 
most of New York City (13). To test this hypothesis, results 
of environmental sampling would need to be correlated 
with cases of human disease (14,15).
Our study provided an opportunity to study risk factors 
in a population without referral center bias that can occur 
in centers specializing in NTM care. The predominance of 
women among persons with NTM disease is consistent with 
previous reports (12,16). For pulmonary disease caused by 
MAC, the greater proportion of affected women appeared 
to reﬂ  ect the higher proportion of women in the older age 
strata of the base population of NYPH. The correlation of 
NTM disease with gender did not appear to be attributable 
to a higher prevalence of concurrent medical conditions or 
concomitant medication use among women. For example, 
chronic obstructive pulmonary disease  is the most com-
mon risk factor for pulmonary disease with NTM, but it 
is more prevalent among men than women in the United 
States (89 vs. 61 per 1,000 persons) (17,18). We speculat-
ed that cosmetic surgery could explain, in part, the higher 
risk of nonrespiratory tract disease in women, although the 
number of these procedures performed during the study pe-
riod was unavailable, and cosmetic surgery accounted for 
only a small number of cases (19–21). We were also able 
to uniquely examine the effect of race. As in previous stud-
ies, most cases of NTM disease occurred in white persons 
(3), but our base population was unique in having a lower 
proportion of whites. Furthermore, the higher prevalence 
of NTM disease noted in whites in our study could not be 
attributed to cystic ﬁ  brosis because only 4 subjects had this 
medical condition (22–26).
Only one-third of patients with positive cultures for 
NTM were categorized with disease. A signiﬁ  cantly higher 
proportion of patients with positive cultures for RGM, M. 
kansasii, or M. marinum were considered to have NTM 
disease than patients with MAC (27). Although respiratory 
tract isolates were most common (28,29), most reﬂ  ected 
colonization or contamination. Thus, laboratory-based sur-
veillance may reasonably estimate the incidence of nonres-
piratory tract disease caused by RGM, M. kansasii, and M. 
marinum but provide less accurate estimates of the inci-
dence of MAC disease and of respiratory tract disease.
Among the expected risk factors for NTM disease, we 
found that preexisting pulmonary conditions were most 
common. However, many cases of NTM disease occurred 
in patients with concurrent illnesses or medications that 
were immunosuppressive. Our ﬁ  nding that MAC was the 
most common pathogen causing posttransplant NTM dis-
ease was consistent with results of prior studies (30,31). 
Notably, one fourth of patients with NTM disease did not 
have a known risk factor, which suggests the possibility of 
a unique genetic susceptibility or environmental exposure.
Our study did have limitations. We used a conve-
nience sample of patients receiving care at our medical 
center, which introduced potential bias if our sample was 
not representative of the general population. Our ﬁ  ndings 
may not be applicable to other geographic regions, particu-
larly given the different rates of disease we noted among 
different areas in New York City. The rare nature of NTM 
disease makes an accurate measure of the incidence in the 
population exceptionally difﬁ  cult. Our incidence rate cal-
culation was a gross estimate and likely an underestimate. 
Patients residing in the selected base population may have 
sought care elsewhere; patients with positive cultures and 
presumptive colonization may have progressed to active 
disease; and our case-patients were often hospitalized at the 
time of diagnosis, which suggests limited detection of out-
patient cases. In addition, the high proportion of hospital-
ized case-patients could overestimate coexisting illnesses 
and concomitant medications. Potential cases of respiratory 
tract disease could have been missed due to incomplete 
data, usually a lack of chest CT results. Cultures or radio-
graphic imaging may have been performed at other medi-
cal facilities, which could have resulted in misclassiﬁ  cation 
of disease status. Racial differences could reﬂ  ect, in part, 
differential access to healthcare. Furthermore, although 
CUMC is not a referral center for NTM, it is a referral cen-
ter for other conditions, including lung transplantation. 
In conclusion, we found an increased incidence of 
NTM-positive cultures and disease compared with results 
in previous reports. Our results suggest that laboratory-
based surveillance may produce reasonable estimates of 
the incidence of nonrespiratory tract disease and of disease 
caused by RGM, M. kansasii, and M. marinum. However, 
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such surveillance is relatively inaccurate for estimating 
the incidence of pulmonary disease and disease caused by 
MAC. Larger, multicenter regional studies or mandatory 
reporting will be required to better understand the changing 
epidemiology of NTM in patients without HIV infection. 
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